Phase II study of S-1 plus amrubicin as the 2nd-line treatment for non-small cell lung cancer without EGFR mutation.
Phase of Trial: Phase II
Latest Information Update: 18 Nov 2013
At a glance
- Drugs Amrubicin (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 18 Nov 2013 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 25 May 2011 New trial record